Business
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., March 25, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported positive topline results from the PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH) and reported fourth quarter and year end 2024 financial results.
About this update from Kezar Life Sciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1100,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/11e40a56aacd64328acd1e3406837236"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/q1HHS5toHo0OOMmxnK.4PQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/11e40a56aacd64328acd1e3406837236","width":960,"height":314},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/u_Kblly0849nbQ.Fz_Mllw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyMDA7aD03MjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/11e40a56aacd64328acd1e3406837236","width":1100,"height":360}},"lazy":false},{"type":"text","content":"Company-hosted conference call and webcast to be held today at 8:00 a.m. ET","length":75,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Zetomipzomib treatment results in steroid-sparing biochemical remissions in accordance with AASLD treatment guidelines in a difficult-to-treat, refractory AIH patient population.","length":178,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"In relapsed, steroid-dependent AIH patients, of the 21 of 24 entering screening on steroid-based therapy, 36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg/day or less, compared to 0 of 7 of placebo patients.","length":300,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"In the intention-to-treat (ITT) population, 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper (≤5 mg/day), compared to 1 of 8 placebo patients.","length":164,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Median duration of response in zetomipzomib patients achieving a CR was 27.6 weeks (including the ongoing open-label extension), and no disease flares were reported in any zetomipzomib-treated patient achieving CR during study.","length":227,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Favorable safety profile was observed during the 6-month, blinded treatment period.","length":83,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash, cash equivalents and marketable securities totaled $132 million as of December 31, 2024","length":9...